孟鲁司特联合氯雷他定治疗过敏性鼻炎的临床效果观察

Clinical observation of efficacy of Montelukast combined with Loratadine in treatment of allergic rhinitis

目的:观察孟鲁司特联合氯雷他定治疗过敏性鼻炎的临床效果。方法:选取80例过敏性鼻炎患者作为研究对象,按随机数字表法将其分为对照组和观察组各40例,对照组给予氯雷他定治疗,观察组在对照组的基础上联合孟鲁司特治疗,比较两组症状积分、临床疗效、免疫功能指标水平及用药安全性。结果:治疗后观察组Th1/Th2、IgE水平及症状积分均明显低于对照组,差异均有统计学意义(P<0.05);观察组的治疗有效率为95.00%(38/40),明显高于对照组的77.50%(31/40),差异有统计学意义(P<0.05)。结论:与单用氯雷他定相比,孟鲁司特联合氯雷他定治疗过敏性鼻炎的效果更显著,可有效减轻患者症状,改善免疫功能指标水平,且用药安全性高。

Objective:To investigate clinical effects of Montelukast Combined with Loratadine in treatment of allergic rhinitis.Methods:80 patients with allergic rhinitis were selected as the study subjects.They were divided into control group and observation group according to the random number table method, 40 cases in each group.The control group was treated with Loratadine, while the observation group was given Montelukast on the basis of that of the control group.The symptom score, clinical efficacy, immune function indicator levels and medication safety were compared between the two groups.Results:After the treatment, the levels of Th1/Th2, IgE and symptom scores in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P<0.05).The effective rate of the observation group was 95.00%(38/40), which was significantly higher than 77.50%(31/40) of the control group, and the difference was statistically significant (P<0.05).Conclusions:Compared with Loratadine alone, Montelukast combined with Loratadine in the treatment of allergic rhinitis is more effective.Moreover, it can effectively reduce the symptoms of the patients and improve the levels of the immune function indicators with high safety.